AI-aided protein design requires massive amounts of data to train the models on. The field of antibody development has struggled to provide the high-quality biological data that is needed for good AI models to generate results: “Drug discovery has a biological data problem,” says CEO McClain. Absci has been collecting antibody data over the past decade, which has allowed the company to build its zero-shot generative AI method.
The happy marriage of synthetic biology and AI that has enabled creating new antibodies with the exact specifications you want was made possible thanks to another unlikely hero in this story. An important piece of the technology that positioned Absci for success was figuring out how to manufacture antibodies in, the model organism of synthetic biology. Traditionally, antibodies are made in mammalian cells, which are slower to grow and harder to manipulate.
What an outstanding achievement by who ever is behind the running of operations of the company involved.
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: WOKVNews - 🏆 247. / 63 Read more »
Source: FoxNews - 🏆 9. / 87 Read more »
Source: verge - 🏆 94. / 67 Read more »
Source: DigitalTrends - 🏆 95. / 65 Read more »